Author of

• 31932

  +

  EP1.04 - Immuno-oncology (ID 194)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Immuno-oncology
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 31954

    +

    EP1.04-19 - First Experience with Atezolizumab in Slovakia (Now Available) (ID 2869)

    08:00 - 18:00  |  Author(s): Robert Godal
    • Abstract
    • Slides

    Background
    

    New immunotherapeutics, PD-1 and PD-L1 checkpoint signalling inhibitors, have improved the prospects of patients with advanced non-small cell lung cancer (NSCLC). The purpose of this study was to assess the first results achieved with the PD-L1 inhibitor atezolizumab in the treatment of advanced NSCLC in Slovakia.

    Method
    

    The data of patients who entered the pre-approval access programme with atezolizumab between June 2017 and September 2017 were reviewed in the retrospective multicentre study. Data regarding patients were obtained from the databases of participating institutions and patient files. Statistical analyses were performed using MedCalc^®software. PFS and OS were estimated using the Kaplan–Meier method, based on the data available by the end of March 2019.

    Result
    

    Altogether 22 patients were included. Characteristics of patients: median age, years (range): 63 (41 - 85), female/male: 3/19, ECOG PS: 0, 1, 2, 3 in 6, 11, 3, 2 patients, respectively. Histology: 8 squamous, 14 non-squamous. Patients with locally advanced disease: 1, with metastatic disease: 21. Treatment lines before atezolizumab: median: 2 (range: 1 - 3). Median PFS: 5 months (95%CI: 4 - 10). Median OS: 11 months (95%CI: 8 – 20). Complete/partial response: 1/4 patients. Median PFS in patients with complete or partial response was not achieved but will be over 19 months (range: 13 – 21+). Two patients only had to discontinue atezolizumab due to toxicities (pneumonitis and hepatitis).

    Conclusion
    

    Results from our retrospective study are similar to those seen in the phase III trial OAK, excepting PFS. However, the different CT scanning schedules for the response evaluations and follow up in the different participating institutions could influence numerically better PFS seen in our patients.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.